We are more than a technology partner. We work to understand your business goals and collaborate with you to deliver sustainable solutions for you and your customers.
From formulation development to commercial manufacturing, we design and produce our products at our cGMP facility in Oxnard, CA.
Replace injections and lessen pharma’s $637 billion in annual sales that are lost annually due to non-adherence
Widen a drug’s therapeutic index and provide a new avenue for toxic drugs. CURE’s technology can improve the efficacy and safety of new and existing drugs.
Eliminate the need to swallow and increase palatability for children, the elderly and patients with neurologic disorders. Deliver multiple actives at once for a combination therapies.
Facilitate patient-specific dosing. Our technology can be dispensed with great accuracy for drugs that need careful titration and patients requiring individualized doses.
Deliver faster symptom relief, sustained release or a combination thereof. Our platform can stabilize plasma levels over extended time periods.
Create market differentiation in response to expiring patents, generic encroachment, and declining new drug pipelines.
We engage from early feasibility through commercialization.
We apply the highest standards of rigour and innovation into every CUREfilm formulation. Our industry leading scientists are pioneers in formulating proprietary and non-proprietary molecules, leveraging proprietary computational analysis methods.
Process development is at the core of CURE’s product commercialization activities. The process development team works closely with research and development to ensure that product specifications can be successfully achieved in downstream manufacturing operations.
CURE operates a cGMP state-of-the-art production plant in an FDA registered and audited facility, which features a class 100,000 CRT humidity-controlled clean room environment. We manufacture technically complex formulations that meet exacting standards for quality and effectiveness. Our comprehensive Quality Management System encompasses every part of the manufacturing process, starting with the procurement of raw materials to the delivery of product to our customers. Our standards, protocols, and validated processes ensure consistent high quality.
We work collaboratively with our clients to identify, design and access the best solutions for both primary and secondary packaging.
We are sponsoring cancer discovery research in the laboratory of Dr. Dedi Meiri at the Technion Institute of Technology to evaluate the antitumor effects of phytocannabinoids and terpenes on various cancer driving mutations and pathways and to elucidate the mechanism of cannabinoid-mediated antitumor effects.
Hospital Assuta is our lead clinical partner to conduct clinical trials for cannabinoid products in Isreal.
CannaKids CEO, Tracy Ryan, a cannabis advocate on behalf of her daughter, Sophie, is an advisor to Cure.
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-110 targets the treatment of the symptoms of Tourette Syndrome; and THX-130 targets the high-value and under-served market of mild cognitive impairments and Traumatic Brain Injury (TBI). Please visit our website for more information at www.therapixbio.com
Shimadzu, a well-know analytical instrument manufacturer, has been making a name for itself in the scientific cannabis space with a number of exciting new ventures. They have worked extensively with cannabis laboratories throughout the country in refining methods and improving analytical chemistry in the space.